NCT07278882 Using Mobile Technology-assisted Outpatient Maintenance Therapy Pediatric ALL
| NCT ID | NCT07278882 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Institute of Hematology & Blood Diseases Hospital, China |
| Condition | Pediatric Acute Leukemia |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2025-12-01 |
| Primary Completion | 2027-11-20 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2025-12-01 with a primary completion date of 2027-11-20.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To assess the efficacy of using mobile technology to improve the percentage of time wherein drug dosing is within the target range
Eligibility Criteria
Inclusion Criteria: 1. \< 16 years old at diagnosis; 2. having demonstrated ≥ 3 months of \> 90% compliance with using a mobile app to log in records of daily medication and weekly blood test results; 3. no further in-hospital chemotherapy; 4. patient or legal guardian provides informed consent. Exclusion Criteria: None
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07278882 clinical trial?
This trial is open to participants of all sexes, up to 16 Years, studying Pediatric Acute Leukemia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07278882 currently recruiting?
Yes, NCT07278882 is actively recruiting participants. Contact the research team at fengyahui@ihcams.ac.cn for enrollment information.
Where is the NCT07278882 trial being conducted?
This trial is being conducted at Tianjin, China.
Who is sponsoring the NCT07278882 clinical trial?
NCT07278882 is sponsored by Institute of Hematology & Blood Diseases Hospital, China. The trial plans to enroll 100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.